PT1492561E - Metodo para tratar disturbios da glandula mamaria - Google Patents

Metodo para tratar disturbios da glandula mamaria

Info

Publication number
PT1492561E
PT1492561E PT03815338T PT03815338T PT1492561E PT 1492561 E PT1492561 E PT 1492561E PT 03815338 T PT03815338 T PT 03815338T PT 03815338 T PT03815338 T PT 03815338T PT 1492561 E PT1492561 E PT 1492561E
Authority
PT
Portugal
Prior art keywords
disturbles
mammary gland
treating mammary
treating
neuroblastoma
Prior art date
Application number
PT03815338T
Other languages
English (en)
Inventor
Mitchell F Brin
Stephen Donovan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32867445&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1492561(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of PT1492561E publication Critical patent/PT1492561E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Processing Of Meat And Fish (AREA)
  • Steroid Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
PT03815338T 2002-02-08 2003-02-04 Metodo para tratar disturbios da glandula mamaria PT1492561E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/071,826 US7838007B2 (en) 1999-12-07 2002-02-08 Methods for treating mammary gland disorders

Publications (1)

Publication Number Publication Date
PT1492561E true PT1492561E (pt) 2006-10-31

Family

ID=32867445

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03815338T PT1492561E (pt) 2002-02-08 2003-02-04 Metodo para tratar disturbios da glandula mamaria

Country Status (12)

Country Link
US (2) US7838007B2 (pt)
EP (3) EP1492561B1 (pt)
JP (2) JP4889220B2 (pt)
AT (1) ATE331527T1 (pt)
AU (1) AU2003225549B2 (pt)
BR (1) BR0307496A (pt)
CA (1) CA2478902C (pt)
DE (1) DE60306505T2 (pt)
DK (1) DK1492561T3 (pt)
ES (1) ES2264041T3 (pt)
PT (1) PT1492561E (pt)
WO (1) WO2004071525A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
CA2413301A1 (en) * 2000-06-28 2002-01-03 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
EP2272340B1 (en) 2002-08-19 2018-03-14 Ira Sanders Botulinum toxin
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US8084041B2 (en) * 2003-01-24 2011-12-27 Albert Einstein College Of Medicine Of Yeshiva University Use of mycrobacterial vaccines in CD4+ or CD8+ lymphocyte-deficient mammals
US9060993B2 (en) * 2003-05-09 2015-06-23 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
WO2006086001A2 (en) * 2004-07-20 2006-08-17 Allergan, Inc. Thermographic assessment of clostridial toxin applications
US20070258900A1 (en) * 2004-07-20 2007-11-08 Joseph Francis Blood Flow Assessment of Clostridial Toxin Applications
US8343929B2 (en) * 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
EP2168594B1 (en) 2004-09-23 2015-04-29 Toxcure, Inc. Treating neoplasms with neurotoxin
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US8155408B2 (en) * 2008-04-15 2012-04-10 General Electric Company Standardized normal database having anatomical phase information
ES2599033T3 (es) 2008-11-26 2017-01-31 Toxcure, Inc. Tratamiento de neoplasias con neurotoxina
US8629103B2 (en) 2010-12-02 2014-01-14 New York University Treatment of non-proliferative cystic disease of the breast
WO2012097189A1 (en) * 2011-01-13 2012-07-19 Rutgers, The State University Of New Jersey Systems and methods for multi-protocol registration and tissue classification using local morphologic scale (lms)
JP6092205B2 (ja) 2011-07-14 2017-03-08 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 性的行為に関連した失禁の治療方法
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
WO2013153191A1 (en) 2012-04-13 2013-10-17 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (ii)
WO2020047159A1 (en) 2018-08-28 2020-03-05 Ira Sanders Skin therapeutics

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5466672A (en) 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ES2238969T3 (es) 1994-05-09 2005-09-16 William J. Binder Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas.
US5595740A (en) 1994-05-16 1997-01-21 University Of Florida Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
ES2385130T3 (es) * 1997-07-15 2012-07-18 The Regents Of The University Of Colorado, A Body Corporate Uso de terapia con neurotoxinas para el tratamiento de enfermedades urológicas y de enfermedades relacionadas
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
DE19802569A1 (de) 1998-01-23 1999-09-09 Univ Albert Ludwigs Freiburg Toxikologisch aktive Fragmente des lethalen Toxins von Clostridium sordellii und deren Verwendung in Immuntoxinen
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
CN1324246A (zh) 1998-10-27 2001-11-28 梅约医学教育与研究基金会 增加伤口愈合的方法
DE19852981A1 (de) 1998-11-17 2000-05-18 Martin Schmidt Botulinum-Toxine, deren Derivate, Analoge und molekulare Bruchstücke zur topischen epicutanen Anwendung auch in Zusammenwirken mit hautpenetrationsfördernden Substanzen und Maßnahmen in Zubereitungsformen zur Beeinflussung acetylcholinabhängiger Körperfunktionen
DE19856052A1 (de) 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
WO2000062746A1 (en) 1999-04-16 2000-10-26 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
WO2002009743A1 (en) 2000-08-02 2002-02-07 Allergan Sales, Inc. Method for treating a neoplasm
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses

Also Published As

Publication number Publication date
ES2264041T3 (es) 2006-12-16
AU2003225549B2 (en) 2006-11-16
AU2003225549A1 (en) 2004-09-06
DE60306505T2 (de) 2007-01-11
DK1492561T3 (da) 2006-09-25
EP1728517A3 (en) 2008-06-25
JP2006510723A (ja) 2006-03-30
US20050260231A1 (en) 2005-11-24
CA2478902A1 (en) 2004-08-26
WO2004071525A1 (en) 2004-08-26
DE60306505D1 (de) 2006-08-10
US7838007B2 (en) 2010-11-23
JP4889220B2 (ja) 2012-03-07
EP1492561A1 (en) 2005-01-05
US7846456B2 (en) 2010-12-07
ATE331527T1 (de) 2006-07-15
EP1728517A2 (en) 2006-12-06
US20020094339A1 (en) 2002-07-18
EP1492561B1 (en) 2006-06-28
BR0307496A (pt) 2005-06-28
JP2012025775A (ja) 2012-02-09
CA2478902C (en) 2012-05-01
EP2204183A1 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
PT1492561E (pt) Metodo para tratar disturbios da glandula mamaria
ATE446769T1 (de) Botulintoxin-therapie für hauterkrankungen
BR0114054A (pt) Método para tratar alergias usando pirazóis substituìdos
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
CY1116992T1 (el) Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DE60330889D1 (de) Botulinum toxin zur behandlung von magengeschwür und gastroösophagealen reflux
WO2006138127A3 (en) Botulinum toxin and the treatment of primary disorders of mood and affect
EA200401365A1 (ru) Способы лечения илеуса
BRPI0416268A (pt) composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
ECSP066484A (es) Compuestos y metodos para el tratamiento de dislipidemia
DK1383508T3 (da) Doxycyclin til behandling af acne
BR0308813A (pt) Tratamento de tuberculose usando derivados de pleuromutilina
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
DK1545609T3 (da) Antistoffer rettet mod oxideret apolipoprotein B
ATE393625T1 (de) Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen
BRPI0514836A (pt) uso de toxina botulìnica para tratamento de uma deformidade da nádega
PL373528A1 (en) Medicine for preventing and treating bromidrosis
NO20032406L (no) Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens
DE60335093D1 (de) Verwendung von nichtantibakteriellen tetrazyklin-analoga und ihren formulierungen für die behandlung von bakteriellen exotoxinen
DE602005010676D1 (de) Behandlung von druckgeschwüren
BR0208593A (pt) método para o tratamento de um mamìfero, composto, e, composição farmacêutica
DE60322395D1 (de) Antipruritisches mittel
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten